Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.
Yan, R., Wang, R., Ju, B., Yu, J., Zhang, Y., Liu, N., Wang, J., Zhang, Q., Chen, P., Zhou, B., Li, Y., Shen, Y., Zhang, S., Tian, L., Guo, Y., Xia, L., Zhong, X., Cheng, L., Ge, X., Zhao, J., Wang, H.W., Wang, X., Zhang, Z., Zhang, L., Zhou, Q.(2021) Cell Res 31: 517-525
- PubMed: 33731853 
- DOI: 10.1038/s41422-021-00487-9
- Primary Citation of Related Structures:  
7CZP, 7CZQ, 7CZR, 7CZS, 7CZT, 7CZU, 7CZV, 7CZW, 7CZX, 7CZY, 7CZZ, 7D00, 7D03, 7D0B, 7D0C, 7D0D - PubMed Abstract: 
Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against coronavirus disease 2019 (COVID-19). We isolated a large number of nAbs from SARS-CoV-2-infected individuals capable of disrupting proper interaction between the receptor binding domain (RBD) of the viral spike (S) protein and the receptor angiotensin converting enzyme 2 (ACE2) ...